Form 4: Intra-Cellular Therapies Director Riggs Acquires Shares
SEC Form 4 Filing
Director Rory B. Riggs acquired 260 shares of Intra-Cellular Therapies, Inc. at $69.20 per share on March 31, 2024.
Summary
- On March 31, 2024, Rory B. Riggs, a director of Intra-Cellular Therapies, Inc., acquired 260 shares of common stock at a price of $69.20 per share.
- Following the transaction, Riggs directly owns 99,495 shares of Intra-Cellular Therapies, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a director purchasing shares, which can be seen as a mildly positive signal, but it's not a major event.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and are closely watched by investors for signals about management's view of the company's prospects.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2024 | Date of transaction: Rory B. Riggs acquired shares of Intra-Cellular Therapies, Inc. |
| 04/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.